Certain determinants of HRQOL in CKD, namely anemia and depression, are treatable.
Early identification and correction may improve overall well being of patients. Clinical trials …

Background Several erythropoiesis‐stimulating agents (ESAs) are available for treating
anaemia in people with chronic kidney disease (CKD). Their relative efficacy (preventing …

Renal anemia is a complication of chronic kidney disease. Guidelines for safe and effective
treatment in patients with renal anemia are needed. The Japanese Society for Dialysis …

BACKGROUND: Targeting higher hemoglobin levels with erythropoiesis-stimulating agents
(ESAs) to treat the anemia of chronic kidney disease (CKD) is associated with increased …

Background Metabolic acidosis, a complication of chronic kidney disease, causes protein
catabolism and bone demineralisation and is associated with adverse kidney outcomes and …

Background Patients with advanced chronic kidney disease lose the capacity to fully excrete
endogenous acid, resulting in chronic metabolic acidosis that increases the risk of disease …

Objective Conflicting findings and knowledge gaps exist regarding links between anemia,
physical activity, health-related quality of life (HRQOL), chronic kidney disease (CKD) …

Background: The efficacy of erythropoietin-stimulating agents (ESAs) for improving health-
related quality of life (HRQOL) in anemia of chronic kidney disease (CKD) is unclear …

Background. One of the cardinal symptoms of anemia in chronic kidney disease (CKD)
patients is fatigue. Recently, results from Trial to Reduce Cardiovascular Events with …

Background Chronic kidney disease is a significant contributor to mortality and morbidity
worldwide, and the number of people who require dialysis or transplantation continues to …